All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
BXCL701 granted orphan drug designation by the US FDA for the treatment of AML
The United States (US) Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) to BXCL701 for the treatment of acute myeloid leukemia (AML).1 BXCL701 has already received ODD for the treatment of melanoma and pancreatic cancer.1
The company responsible for the development of the drug is planning to test BXCL701 as monotherapy, and as combination therapy, in specific patients with AML for whom there is a high unmet medical need.1
About BXCL7011
- Orally-available systemic innate immunity activator:
- Inhibits dipeptidyl dipeptidases DPP8 and DPP9
- Blocks immune evasion via targeting of the fibroblast activation protein (FAP)
- Exerts an immuno-stimulatory effect by initiating pro-inflammatory, programmed, lytic cell death (pyroptosis)
- In a study published by Darren C. Johnson and colleagues in Nature Medicine, small-molecule inhibitors of the DPP8 and DPP9 were shown to:2
- Cause pyroptosis in most human AML cell lines and primary AML samples, whilst leaving cells from other lineages unaffected
- Prevent AML progression in mouse models
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?